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Background: Goserelin plus aromatase inhibitors (AI) have already been used in male advanced breast cancer, but
the cases that fulvestrantin male breast cancer are rare.
Case presentation: Here we report a case of long-term (3 years) response to Goserelin plus continuing endocrine
treatments given for a male advanced breast cancer. The patient prolongs his life with high life quality, and has
more time with his family.
Conclusion: Goserelin plus endocrine treatments may benefit male breast cancer.
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Breast cancer in men is relatively rare, and most breast
cancers in men are estrogen receptor/progesterone recep-
tor positive. Tamoxifen remains the standard adjuvant
treatment and is also the mainstay first-line treatment for
advanced disease. However, the role of AI and fulvestrant
remains controversial. We have already used goserelin
plus aromatase inhibitors (AI) in male advanced breast
cancer, but the cases in which fulvestrant has been used in
male breast cancer are rare.Case presentation
A 44-year-old man was diagnosed with a left breast cancer
(pT1N1M0) after left modified radical mastectomy in local
hospital. The tumor was ER-positive, PgR-negative, and
HER-2-negative as evaluated by immunohistochemistry.
The patient received CAF(Cytoxan+doxorubicin+5-Fu) ad-
juvant chemotherapy with six cycles, and tamoxifen was ad-
ministered for 3 years. In 2008, metastasis was found in the
sternum and scapula by skeleton ECT(emission computed
tomography) scan. Sternum dissection was carried out
followed by radiotherapy (60 Gy total dose), and two cycles
of chemotherapy with docetaxel and cisplatin were given,
followed by four cycles of docetaxel and capecitabine, and* Correspondence: jiangzefei@medmail.com.cn
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line endocrine treatment, but discontinued after 7 months
because of disease progression.
In October 2009, the patient went to our hospital and
was diagnosed with multiple bone and lung metastases on
chest computed tomography (CT). He received Goserelin
plus anastrozole as a second-line endocrine treatment,
which resulted in stable disease for 12 months prior to
progression. Goserelin plus exemestanewas started as a
third-line endocrine treatment, which also resulted in
stable disease for 11 months. He received 10 months of
medroxyprogesterone prior to further progression of lung
disease. In August 2012, Goserelin plus fulvestrant(500
mg/d,1,250 mg intramuscular monthly)was initiated as the
fifth-line endocrine treatment. The lung metastasis shrank
after 2 months and the patient is still on treatment. De-
tailed treatment information is given Table 1.
Discussion
Male breast cancer is rare, accounting for 1% of all breast
cancer, and is also rare in male malignant tumors. Endocrine
treatments are important in hormone-receptor-positive
male breast cancer. Tamoxifen remains the gold-standard
adjuvant treatment. Anastrozole, letrozolea and exemes-
tane as AI can inhibit the action of the enzyme aromatase,
which converts androgens into estrogens by a process
called aromatization, therefore are used in the treatmenthis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Patient’s treatment after metastasis
Treatment line Start and stop time, year/month Sites of metastasis Therapeutic schedule Best efficacy TTP
1st 2008/8 to 2008/10 Bone Docetaxel + cisplatin SD TTP = 2 months
2nd 2008/10 to 2008/12 Bone Docetaxel + capecitabine SD TTP = 4 months
3rd 2009/3 to 2009/10 Bone Letrozole SD TTP = 7 months
4th 2009/10 to 2010/10 Bone,lung Goserelin + anastrozole SD TTP = 12 months
5th 2010/10 to 2011/9 Bone,lung Goserelin + exemestane SD TTP = 11 months
6th 2011/9 to 2012/7 Bone,lung Medroxyprogesterone SD TTP = 10 months
7th 2012/8 to 2013/2 Bone,lung Goserelin + fulvestrant SD 6+ months
SD stable disease, TTP time to progression.
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releasing hormone superagonist, also known as a
luteinizing hormone-releasing hormone (LHRH) agon-
ist, and is used to suppress production of the sex hor-
mones (testosterone and estrogen). For male breast
cancer, goserelin,which suppresses production of tes-
tosterone, may be better for the effect of AI. Medro-
xyprogesterone is a potent full agonist of the AR
(androgen receptor) by hypothalamus pituitary adrenal
axis suppression. Its activation of the AR has been
shown to play an important and major role in its anti-
gonadotropic effects and in its beneficial effects against
breast cancer. This patient was treated with goserelin
plus AI and maintained long-term clinical benefit. To
date there has been little clinical study onthe subse-
quent treatment after disease progression following AI
treatment for male breast cancer.
Fulvestrant is novel steroidal ER antagonist lacking
agonist effects. By covalent binding to the ER, receptors
are rapidly downregulated, resulting in a decrease of
cellular ER levels and complete abrogation of estrogen-
sensitive gene transcription [1].In postmenopausal
women, fulvestrant has been shown to be effective and
safe in patients in whom tamoxifen or AI have failed
[2]. At present, some clinical studies of fulvestrant used
in male breast cancer have been reported [3]. However,
endocrine treatment with Goserelin plus fulvestrant for
male breast cancer has not been reported in the lite-
rature so far. Our patient is a 44-year-old man, so
we thought Goserelin,which suppresses production of
testosterone may be beneficial with fulvestrant. He has
hormone-dependent breast cancer, and sustainable
endocrine treatments have achieved long-lasting clin-
ical benefit (3 years).
Since 2009, the patient was under easy endocrine
treatments, with good tolerability, avoiding adverse ef-
fects of chemotherapy, and improved quality of life. He
had more time with his family and work in society.Our
oncologist proposes that the treatment for advanced
breast cancer should prolong survival, maintain quality
of life, and make the patient happy.Conclusion
For male hormone-positive breast cancer goserelin plus
AI or fulvestrant maybe good choices, especially the pa-
tient is hormone-sensitive.
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